HCPCS Level II code J1299 represents a 2 mg unit of eculizumab, a high-cost injectable biologic used in several rare, immune-mediated conditions. Nationally, accurate coding for biologic agents like eculizumab matters for patient access, utilization tracking, and payer coverage determinations because dosing and administration can drive significant cost and clinical-management decisions. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. This publication provides a concise briefing on clinical context, typical sites of service, and the billing constructs relevant to J1299. Readers will find an overview of where J1299 is used clinically, common billing considerations, and the types of benchmarks and policy updates that influence coverage and claim adjudication for injectable biologics. The piece highlights how unit-based HCPCS coding for eculizumab interfaces with infusion services and outpatient settings, and it identifies areas where payers commonly apply utilization management or prior authorization (policy specifics vary by payer). Data not provided in the source are noted as unavailable; this summary focuses on national-level implications rather than jurisdictional policy detail.